Last reviewed · How we verify
NCT05686564
Early Access Program for ALXN1840 in Patients With Wilson Disease
trial testing ALXN1840 in Wilson Disease. No longer available.
Quick facts
| Lead sponsor | Alexion Pharmaceuticals, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- ALXN1840 — full drug profile →
Conditions studied
- Wilson Disease — all drugs for Wilson Disease →
Sponsor
Alexion Pharmaceuticals, Inc. — full company profile →
Who can join
3 and older, any sex, with Wilson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single-arm, multi-center EAP, designed to provide early access to ALXN1840 for eligible patients with WD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05686564
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ALXN1840
Trials testing the same drug.
- NCT05047523 — Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease · Phase 3 · terminated
- NCT04610580 — Bioavailability Study of 2 Oral Formulations of ALXN1840 · Phase 1 · completed
- NCT04526210 — Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants · Phase 1 · completed
- NCT04573309 — Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 · Phase 2 · completed
- NCT04560816 — A Study of the Cardiac Effects of ALXN1840 in Healthy Adults · Phase 1 · completed
Other recruiting trials for Wilson Disease
Currently open trials in the same condition.
- NCT07301216 — Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study · recruiting
- NCT06430359 — Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients · recruiting
- NCT06650319 — A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease · EARLY_PHASE1 · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT03334292 — Natural History of Wilson Disease · recruiting
Other Alexion Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
- NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
- NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
- NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
- NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05686564 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
- Last refreshed: 17 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05686564.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing